Alliqua, Inc. has entered into a licensing agreement with Celgene Cellular Therapeutics (CCT), a subsidiary of Celgene Corp., under which Alliqua receives rights to develop and market the wound care products Biovance and Extracellular Matrix (ECM). In addition to the license agreement, Alliqua will to sell $6 million in common stock to Celgene, which has also appointed a director to Alliqua’s board.   Biovance is a collagen-based decellularized and dehydrated topical wound covering produced from...